Top-News

United Community Banks Aktie News

Aktie
WKN:  A1JB5Q ISIN:  US90984P3038 US-Symbol:  UCB Land:  USA
31,11 $
-0,25 $
-0,80%
26,718 € 22:10:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
16,47%
KGV
14,36
Dividende
0,25 $
Dividendenrendite
0,80%
Index-Zuordnung
-

United Community Banks News

04.12.25 - PR Newswire
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting PR Newswire
13.11.25 - PR Newswire
United Community Climbs 32 Spots on American Banker's 2025 Best Banks to Work For List
United Community Climbs 32 Spots on American Banker's 2025 Best Banks to Work For List PR Newswire
03.11.25 - PR Newswire
/C O R R E C T I O N -- UCB/
/C O R R E C T I O N -- UCB/ PR Newswire
29.10.25 - PR Newswire
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™ PR Newswire
29.10.25 - PR Newswire
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-​noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session PR Newswire
25.10.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
BIMZELX® (bimekizumab-​bkzx) Three-​Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis PR ...
13.10.25 - PR Newswire
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) PR Newswire
17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
BIMZELX® (bimekizumab-​bkzx) New Three-​year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints PR Newswire
17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
BIMZELX® (bimekizumab-​bkzx) Data in Moderate-​to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years PR Newswire
10.09.25 - PR Newswire
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care PR Newswire
29.08.25 - PR Newswire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress PR Newswire
29.08.25 - PR Newswire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress PR Newswire
05.08.25 - PR Newswire
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment PR Newswire
08.07.25 - PR Newswire
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
UCB extends its BIMZELX® "Get Yourself Back" direct-​to-consumer campaign for the hidradenitis suppurativa community PR Newswire
27.06.25 - PR Newswire
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder PR Newswire
20.06.25 - PR Newswire
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference PR Newswire
17.06.25 - PR Newswire
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S. PR Newswire
12.06.25 - PR Newswire
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity PR Newswire
11.06.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
BIMZELX® (bimekizumab-​bkzx) Three-​Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis PR Newswire
19.05.25 - PR Newswire
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »